RxDoctor Payments Data

Irene Padre, NP

Acute Care · West Orange, NJNPI 1245453703

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,826 of the $3,826 with a category attached, or 73.9%. 33 manufacturers reported payments, led by Bristol Myers Squibb at 26.1% of the total. 2025 is the largest year on record at $1,970, more than ten times the $39 reported in 2021. Among acute care clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,826in general payments, 2019–2025

Across 162 payments — averaging $23.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bristol Myers Squibb$1K
  • Amgen$341
  • Merck$279
  • E.r. Squibb & Sons, L.L.C.$230
  • Impulse Dynamics (USA) Inc.$224
  • Atricure, Inc.$199
  • plus $2K from 27 others

What the payments were for

  • Grants$1,00026%
  • Food & beverage$2,82674%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,826 in reported general payments places this provider in the 90th percentile of 656 acute care providers in New Jersey.

See all acute care providers in New Jersey

Medicare billing

Part B allowed, 2024
$9,568
Medicare patients
78
Services billed
93

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban390$435,799
EntrestoSacubitril/Valsartan70$105,498
XareltoRivaroxaban77$88,155
Repatha SureclickEvolocumab70$71,905
JardianceEmpagliflozin32$24,189
Praluent PenAlirocumab22$17,639
FarxigaDapagliflozin Propanediol12$17,183
BrilintaTicagrelor16$12,475
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr16$7,100
LodocoColchicine12$6,816
Metoprolol Succinate403$6,173
Atorvastatin Calcium465$5,671
Carvedilol ErCarvedilol Phosphate11$5,338
Rosuvastatin Calcium305$4,875
Ezetimibe120$3,555

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$80$435,799390 claims
Johnson & JohnsonXarelto$14$88,15577 claims
AstraZenecaFarxiga, Brilinta$105$29,65828 claims
Boehringer IngelheimJardiance$16$24,18932 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 656 acute care providers in New Jersey.

Other acute care in West Orange

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →